These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 7616439

  • 1. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis.
    Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F.
    J Pharmacol Exp Ther; 1995 Jul; 274(1):516-20. PubMed ID: 7616439
    [Abstract] [Full Text] [Related]

  • 2. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
    Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M.
    J Pharmacol Exp Ther; 1996 Jul; 278(1):441-6. PubMed ID: 8764380
    [Abstract] [Full Text] [Related]

  • 3. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
    Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M.
    Proc Natl Acad Sci U S A; 1993 Dec 15; 90(24):11825-9. PubMed ID: 7903454
    [Abstract] [Full Text] [Related]

  • 4. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.
    Broly F, Meyer UA.
    Pharmacogenetics; 1993 Jun 15; 3(3):123-30. PubMed ID: 8101460
    [Abstract] [Full Text] [Related]

  • 5. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE, Relling MV.
    Pharmacogenetics; 1991 Dec 15; 1(3):143-8. PubMed ID: 1688245
    [Abstract] [Full Text] [Related]

  • 6. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction.
    Bathum L, Johansson I, Ingelman-Sundberg M, Hørder M, Brøsen K.
    Pharmacogenetics; 1998 Apr 15; 8(2):119-23. PubMed ID: 10022749
    [Abstract] [Full Text] [Related]

  • 7. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects.
    Dahl ML, Yue QY, Roh HK, Johansson I, Säwe J, Sjöqvist F, Bertilsson L.
    Pharmacogenetics; 1995 Jun 15; 5(3):159-64. PubMed ID: 7550367
    [Abstract] [Full Text] [Related]

  • 8. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
    Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M.
    Pharmacogenetics; 1999 Dec 15; 9(6):715-23. PubMed ID: 10634134
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML, Johansson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F.
    Clin Pharmacol Ther; 1992 Jan 15; 51(1):12-7. PubMed ID: 1346258
    [Abstract] [Full Text] [Related]

  • 11. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.
    Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M.
    Mol Pharmacol; 1994 Sep 15; 46(3):452-9. PubMed ID: 7935325
    [Abstract] [Full Text] [Related]

  • 12. [Prevalence of ultraextensive drug metabolizers in Croatian population--long-PCR based detection of amplified CYP2D6 gene].
    Bozina N, Tramisak I, Granić P, Puljević D, Stavljenić-Rukavina A.
    Lijec Vjesn; 2002 Sep 15; 124(3-4):63-6. PubMed ID: 18958918
    [Abstract] [Full Text] [Related]

  • 13. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene.
    Løvlie R, Daly AK, Molven A, Idle JR, Steen VM.
    FEBS Lett; 1996 Aug 19; 392(1):30-4. PubMed ID: 8769309
    [Abstract] [Full Text] [Related]

  • 14. Debrisoquine hydroxylation genotype in familial forms of idiopathic Parkinson's disease.
    Bordet R, Broly F, Destée A, Libersa C.
    Adv Neurol; 1996 Aug 19; 69():97-100. PubMed ID: 8615190
    [No Abstract] [Full Text] [Related]

  • 15. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
    Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, Bertilsson L.
    Clin Pharmacol Ther; 2001 Oct 19; 70(4):327-35. PubMed ID: 11673748
    [Abstract] [Full Text] [Related]

  • 16. Phenotype/genotype relationships for the cytochrome P450 enzyme CYP2D6 in rheumatoid arthritis: influence of drug therapy and disease activity.
    Beyeler C, Daly AK, Armstrong M, Astbury C, Bird HA, Idle JR.
    J Rheumatol; 1994 Jun 19; 21(6):1034-9. PubMed ID: 7932410
    [Abstract] [Full Text] [Related]

  • 17. Debrisoquine polymorphism: novel CYP2D6 gene Bam HI restriction fragment length polymorphism in the Ngawbé Guaymí Indian of Panama.
    Petersen DD, Kong AN, Jorge LF, Nebert DW, Arias TD.
    Pharmacogenetics; 1991 Dec 19; 1(3):136-42. PubMed ID: 1688244
    [Abstract] [Full Text] [Related]

  • 18. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.
    Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA.
    DNA Cell Biol; 1991 Oct 19; 10(8):545-58. PubMed ID: 1681816
    [Abstract] [Full Text] [Related]

  • 19. Quinidine inhibition of debrisoquine S(+)-4- and 7-hydroxylations in Chinese of different CYP2D6 genotypes.
    Bertilsson L, Meese CO, Yue QY, Dahl ML, Ingelman-Sundberg M, Johansson I, Säwe J, Eichelbaum M.
    Pharmacogenetics; 1993 Apr 19; 3(2):94-100. PubMed ID: 8100167
    [Abstract] [Full Text] [Related]

  • 20. Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity.
    Llerena A, Dorado P, Peñas-Lledó EM.
    Pharmacogenomics; 2009 Jan 19; 10(1):17-28. PubMed ID: 19102711
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.